IVD China last week: Roche Diagnostics, Weigao, Hanbon SciTech, BD and JD Health

Roche Diagnostics Breaks Ground on New Investment Project in Suzhou

On May 13, Roche Diagnostics Products (Suzhou) Co., Ltd. (“Roche Diagnostics Suzhou”) held a groundbreaking ceremony for its new investment project in Suzhou, following the formal signing in August 2024.

This investment will support the construction of new facilities for the research, development, and manufacturing of diagnostic reagents and instruments. It also aims to promote the localization of Roche’s key product portfolio. The new site is expected to begin operations in 2028. This initiative reaffirms Roche’s commitment to delivering innovative diagnostic solutions to Chinese patients, aiming to enhance early disease detection and monitoring, and to contribute to a healthier future for patients in China and across the Asia-Pacific region.

"Roche Diagnostics Suzhou is a key global R&D and manufacturing base. The new investment project will further strengthen Roche’s full value chain in China, accelerate local R&D and manufacturing, deliver more high-value and innovative products to the Chinese market, and ensure sustainable supply across the Asia-Pacific region,” said Carrie Lan, General Manager of Roche Diagnostics Asia-Pacific Manufacturing Base and R&D Center.

Weigao Blood Purification Debuts on SSE Main Board, Focusing on Hemodialysis 

On May 19, Shandong Weigao Blood Purification Products Co., Ltd. (referred to as “Weigao Blood Purification”, stock code: 603014), a leading enterprise in China’s hemodialysis field, was officially listed on the main board of the Shanghai Stock Exchange. On its first trading day, the company opened at CNY 49.99 per share, representing an 88.64% increase from the issue price.

Weigao Blood Purification is a medical device company integrating R&D, manufacturing, and sales, with a specialization in blood purification products. The company’s IPO was approved on March 26. Its independently developed hemodialyzer series ranks among the industry’s leading products. In 2023, the company held a 32.5% market share in China’s hemodialyzer sector, positioning it at the forefront of the industry. In recent years, the company has seen steady revenue growth, benefiting from the overall expansion of the hemodialysis market.

Hanbon SciTech Lists on STAR Market with RMB 690 Million in Annual Revenue and Valuation Over RMB 4 Billion

On May 16,  Jiangsu Hanbon Science and Technology Co., Ltd. ((referred to as “Hanbon Science and Technology”), a leading domestic manufacturer of liquid chromatography systems, successfully completed its IPO on the STAR Market of the Shanghai Stock Exchange. On its debut day, Hanbon SciTech closed at RMB 48.23, soaring 102.461% in a single day, with a total market capitalization reaching RMB 4.057 billion.

Founded in 1998, Hanbon Science and Technology is a high-tech enterprise focusing on chromatography technology. The company integrates R&D, production, and sales, providing specialized separation and purification equipment, consumables, application technology services, and related technical solutions for sectors such as pharmaceuticals and life sciences. Hanbon expects to achieve revenue of CNY 145 million to 162 million in Q1 2025, up 5.13% to 17.53% from CNY 140 million in the same period of the previous year. Net profit is forecasted at RMB 8.4 million to 14.1 million, representing a year-on-year increase of 46.60% to 146.08%. After deducting non-recurring gains and losses, net profit is expected to reach CNY 7.9 million to 13.6 million, up 50.11% to 158.41% year-on-year.

BD and JD Health Partner to Pioneer a New Model of In-Home Care

Recently, ahead of Mother’s Day and International Nurses Day, BD (Becton, Dickinson and Company) and JD Health officially signed a service cooperation agreement titled “Caring for Bedridden Women's Health: Professional and Compassionate In-Home Nursing Services.” The initiative will launch as a pilot program in Beijing, offering users in-home nursing services provided by licensed JD Health nurses, including hands-on guidance and care instructions for the use of PureWick®.

PureWick® is BD’s globally pioneering solution for female incontinence management, specifically designed to address the challenges of urinary care for bedridden women. The system features a non-invasive catheterization alternative developed to enhance patient comfort and reduce infection risk.

This collaboration marks a significant step in both parties' continued efforts to explore out-of-hospital care solutions. By integrating instant healthcare retail with in-home nursing services, BD and JD Health are jointly advancing a new model of healthcare delivery—ushering in a new milestone where PureWick® services are brought directly to end-users at home.